NO20044390L - Fosinoprilformulering - Google Patents

Fosinoprilformulering

Info

Publication number
NO20044390L
NO20044390L NO20044390A NO20044390A NO20044390L NO 20044390 L NO20044390 L NO 20044390L NO 20044390 A NO20044390 A NO 20044390A NO 20044390 A NO20044390 A NO 20044390A NO 20044390 L NO20044390 L NO 20044390L
Authority
NO
Norway
Prior art keywords
fosinopril
formulation
fosinoprilformulering
fosinoprilat
ace
Prior art date
Application number
NO20044390A
Other languages
English (en)
Inventor
Reynir Eyjolfsson
Original Assignee
Actavis Group Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36715398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20044390(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actavis Group Hf filed Critical Actavis Group Hf
Publication of NO20044390L publication Critical patent/NO20044390L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20044390A 2002-03-19 2004-10-18 Fosinoprilformulering NO20044390L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IS6315A IS1935B (is) 2002-03-19 2002-03-19 Fósínópríl lyfjasamsetning
PCT/IS2003/000013 WO2003077929A1 (en) 2002-03-19 2003-03-19 Fosinopril formulation

Publications (1)

Publication Number Publication Date
NO20044390L true NO20044390L (no) 2004-12-15

Family

ID=36715398

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044390A NO20044390L (no) 2002-03-19 2004-10-18 Fosinoprilformulering

Country Status (13)

Country Link
US (1) US7045511B2 (no)
EP (1) EP1531831B1 (no)
AT (1) ATE314076T1 (no)
AU (1) AU2003208599A1 (no)
DE (1) DE60303041T2 (no)
DK (1) DK1531831T3 (no)
EA (1) EA008171B1 (no)
ES (1) ES2256721T3 (no)
IS (1) IS1935B (no)
NO (1) NO20044390L (no)
PT (1) PT1531831E (no)
UA (1) UA78988C2 (no)
WO (1) WO2003077929A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2322854T3 (es) * 2003-06-26 2009-06-30 Teva Pharmaceutical Industries Limited Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo(3.3.0)-octano-3-carboxilico.
US20050095287A1 (en) * 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
MX2007008392A (es) * 2005-02-11 2007-09-06 Aventis Pharma Inc Esteres de acido propano-fosfinico sustituido.
WO2006100602A2 (en) * 2005-03-22 2006-09-28 Aurobindo Pharma Ltd Immediate release stable solid oral dosage forms op fosinopril
US20080015188A1 (en) * 2006-04-19 2008-01-17 Julia Hrakovsky Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
ATE406173T1 (de) * 2006-07-10 2008-09-15 Teva Pharma Stabile zubereitung enthaltend eine kombination aus einer feuchtigkeitsempfindlichen aktiven substanz und einer zweiten aktiven substanz und verfahren zur herstellung der zubereitung.
US20140179712A1 (en) * 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
CA2330904C (en) 2001-01-11 2006-10-24 Bernard Charles Sherman Fosinopril sodium tablet formulation
MXPA04004170A (es) * 2001-11-02 2004-09-06 Pfizer Prod Inc Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali

Also Published As

Publication number Publication date
AU2003208599A1 (en) 2003-09-29
US7045511B2 (en) 2006-05-16
IS1935B (is) 2004-06-16
ATE314076T1 (de) 2006-01-15
DE60303041D1 (de) 2006-02-02
EP1531831B1 (en) 2005-12-28
PT1531831E (pt) 2006-05-31
WO2003077929A1 (en) 2003-09-25
EA008171B1 (ru) 2007-04-27
EA200401218A1 (ru) 2005-12-29
UA78988C2 (en) 2007-05-10
DE60303041T2 (de) 2006-08-24
EP1531831A1 (en) 2005-05-25
ES2256721T3 (es) 2006-07-16
IS6315A (is) 2003-09-20
DK1531831T3 (da) 2006-05-15
US20050256086A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
CO5590918A2 (es) Formulaciones
CY1109457T1 (el) Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει
MA29854B1 (fr) Nouvelle formulation
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
NO20060847L (no) Substituert 2-aminotetralin til behandling av depresjon
ATE529430T1 (de) Caspase-hemmer-propharmaka
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
MY151295A (en) Pyrimidyl indoline compound
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
MX2009003926A (es) Composiciones de fenilalquilamino-carbamato.
NO20074544L (no) Inhibering av HER2-losriving med matriksmetalloproteaseantagonister
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
MX2009003929A (es) Composiciones de fenilalquil carbamato.
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
DK1531831T3 (da) Fosinoprilformulering
BR0112245B1 (pt) Éster de ácido 4-alcóxi-ciclohexano-1-amino-carboxílico
WO2006031929A3 (en) Thiazolopyridine kinase inhibitors
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
NO20070187L (no) Oralt desintegrerende farmasoytisk preparat omfattende risperidon
SI1806130T1 (sl) Trden farmacevtski sestavek ki obsega irbesartan

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application